SMVT protein may facilitate creatine delivery to the brain

Overcoming Blood-Brain Barrier Restrictions Through SMVT

Delivering medicines to the central nervous system remains a major challenge in pharmaceutical research because the blood-brain barrier restricts the passage of many substances from the bloodstream. However, the barrier contains specialized transport systems that allow essential nutrients to enter the brain, according to the study published in ACS Chemical Neuroscience.

The research team investigated whether the sodium-dependent multivitamin transporter (SMVT), which naturally transports vitamins and essential nutrients around the body, could improve creatine delivery. Creatine plays a central role in cellular energy metabolism by helping cells meet their energy requirements. To test this hypothesis, researchers used computer modeling, laboratory experiments, and mouse studies.

The scientists designed four modified creatine molecules and tested their ability to enter human glioblastoma cells and mouse neurons. They confirmed that SMVT was present and functional in both cell types, with one specific compound, designated as COMP 1, showing particularly promising uptake during the laboratory phase.

Testing COMP 1 in Mouse Models

Following successful cellular tests, the research team administered COMP 1 to mice to observe transport across the blood-brain barrier. Laboratory analyses showed that the compound accumulated in brain tissue.

However, the recorded concentration revealed notable limitations. The amount of COMP 1 detected in the brain tissue was substantially lower than normal levels of naturally occurring creatine, and the compound declined relatively quickly after uptake.

The project was carried out at the School of Pharmacy at the University of Eastern Finland as part of the doctoral research projects of Adéla Králová and Ville Kuorikoski. Financial support for the work came from a Proof of Concept grant provided by the Jane and Aatos Erkko Foundation.

Implications for Creatine Transporter Deficiency Syndrome

The findings provide early evidence that SMVT can serve as an alternative route for delivering creatine derivatives into the brain. This discovery may eventually benefit research into creatine transporter deficiency syndrome.

Creatine transporter deficiency syndrome is a rare but severe neurological disorder. Impaired transport of creatine into the brain leads to a range of developmental disabilities, making effective delivery mechanisms an important research goal.

Associate Professor Kristiina Huttunen, who led the study at the University of Eastern Finland, argued for using existing physiological mechanisms rather than trying to bypass them.

“The most significant outcome of this study is that SMVT proved to be a suitable transporter for delivering different types of compounds into the brain. The blood-brain barrier is not merely a barrier; it also contains transport systems that allow essential nutrients to reach the brain. Rather than trying to bypass the blood-brain barrier, our goal is to take advantage of its own transport mechanisms to deliver compounds into the brain. Our results suggest that SMVT could offer a promising new opportunity for this purpose.”

Future Applications in Neurological Therapeutics

Beyond creatine transport, the implications of the study extend to broader pharmaceutical research. Exploiting SMVT could potentially enable more efficient delivery of other therapeutic compounds into the central nervous system.

Researchers stated that the pathway might support the development of more precisely targeted treatments for a wide range of neurological conditions. However, additional studies will be required to determine whether the approach can improve creatine delivery sufficiently to benefit people with the condition.